Breaking: Eiger Biopharmaceuticals (EIGR) Buy Rating Reaffirmed by Analysts at Wedbush Today; The Target Given is $53.0000

May 18, 2018 - By James Guidry

Eiger BioPharmaceuticals, Inc. (NASDAQ:EIGR) Logo

Eiger Biopharmaceuticals (EIGR) Rating Reaffirmed

In an analyst note revealed to investors and clients on 17 May, The Buy rating of Eiger Biopharmaceuticals (EIGR) shares was reiterated at Wedbush, who now has a $53.0000 PT on the stock. Wedbush’s PT would suggest a possible upside of 215.48 % from the previous close of the company.

Eiger BioPharmaceuticals, Inc. (NASDAQ:EIGR) Ratings Coverage

Among 5 analysts covering Eiger Biopharmaceuticals (EIGR), 5 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Eiger Biopharmaceuticals has $3600 highest and $17.0 lowest target. $25.80’s average target is 53.57% above currents $16.8 stock price. Eiger Biopharmaceuticals had 11 analyst reports since December 19, 2017 according to SRatingsIntel. The rating was maintained by Wedbush on Wednesday, April 18 with “Buy”. The firm earned “Buy” rating on Monday, March 12 by Oppenheimer. Wedbush maintained the shares of EIGR in report on Friday, January 5 with “Buy” rating. The firm has “Buy” rating by Jefferies given on Tuesday, January 16. The company was maintained on Monday, May 14 by FBR Capital. The stock of Eiger BioPharmaceuticals, Inc. (NASDAQ:EIGR) earned “Buy” rating by Piper Jaffray on Tuesday, January 16. The rating was maintained by Wedbush with “Buy” on Tuesday, December 19. The rating was maintained by Piper Jaffray with “Buy” on Wednesday, March 21. As per Wednesday, March 21, the company rating was maintained by Oppenheimer. Oppenheimer maintained the stock with “Buy” rating in Friday, May 11 report.

The stock increased 41.77% or $4.95 during the last trading session, reaching $16.8. About 1.29 million shares traded or 1602.10% up from the average. Eiger BioPharmaceuticals, Inc. (EIGR) has declined 11.57% since May 18, 2017 and is downtrending. It has underperformed by 23.12% the S&P500.

Analysts await Eiger BioPharmaceuticals, Inc. (NASDAQ:EIGR) to report earnings on August, 13. They expect $-0.98 EPS, up 26.32 % or $0.35 from last year’s $-1.33 per share. After $-0.84 actual EPS reported by Eiger BioPharmaceuticals, Inc. for the previous quarter, Wall Street now forecasts 16.67 % negative EPS growth.

Eiger BioPharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on providing various products for the treatment of orphan diseases in the United States. The company has market cap of $177.07 million. The Company’s product candidate pipeline includes Lonafarnib for the treatment of hepatitis delta virus infection; PEG-interferon Lambda-1a (Lambda) for HDV infection; Exendin 9-39 for post-bariatric hypoglycemia; and Ubenimex for the treatment of pulmonary arterial hypertension and lymphedema, which are under Phase II clinical trials. It currently has negative earnings.

More recent Eiger BioPharmaceuticals, Inc. (NASDAQ:EIGR) news were published by: Streetinsider.com which released: “After-Hours Stock Movers 05/17: (QTNT) (VJET) (AFSI) Higher; (ARQL) (JWN) (AMAT) Lower (more…)” on May 17, 2018. Also Benzinga.com published the news titled: “Benzinga’s Top Upgrades, Downgrades For May 9, 2018” on May 09, 2018. 247Wallst.com‘s news article titled: “Top Analyst Upgrades and Downgrades: AIG, Baxter, Cisco, Eiger Bio, Energy Transfer, Juniper, NOV, Phillips 66 …” with publication date: May 17, 2018 was also an interesting one.

Eiger BioPharmaceuticals, Inc. (NASDAQ:EIGR) Ratings Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.




Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: